Tacrolimus as Treatment of Breast Cancer-Related Lymphedema

February 8, 2022 updated by: Mads Gustaf Jørgensen, Odense University Hospital

BACKGROUND Breast cancer-related lymphedema is a severe and life-long side-effect to breast cancer treatment. The condition increases the risk of infections and decreases health-related quality of life (HR-QOL) in patients. No prophylactic or curative treatment is currently available for this condition.

CD4+-cells plays a critical role in the development of lymphedema. The cells facilitate inflammation and fibrosis formation in the subcutaneous tissue which inhibits lymphatic regeneration. Tacrolimus is an immunosuppressive and anti-inflammatory macrolide that targets the CD4+-cells. Tacrolimus as treatment of lymphedema has already shown promising results in animal studies. Tacrolimus has the potential to cure an otherwise uncurable and life-long side-effect of BC and will therefore benefit a large number of patients who suffers from BCRL.

AIM To assess the effect of Tacrolimus treatment on breast cancer-related lymphedema METHOD Study design A pilot study with a planned inclusion of 20 patients with a 12 month follow-up period. The purpose of this study is to assess the effect of tacrolimus treatment on lymphedema and HR-QOL. Results are attained from objective measures and questionnaires.

The patients will be seen at a consultation prior to the treatment start and then 3 times hereafter (at 3, 6 and 12 months) as follow up consultations where effect of treatment is evaluated.

Primary endpoint:

- Arm volume measured with water displacement test.

Secondary endpoints:

  • Arm volume measured with measuring tape and calculated with volume of a cone formula
  • Patient-reported outcome measured through the Danish versions of , LYMPH-ICF, DASH and SF-36 questionnaires
  • Bioimpedance
  • Lymphangiography Primary- and secondary endpoint data will be collected at each of the 3 consultations (prior to treatment and 3 and 6 months after the treatment start).

CLINICAL IMPACT This will be the first clinical pharmacological study on regarding treatment of lymphedema with Tacrolimus. This study will test the feasibility and efficacy of Tacrolimus ointment in a population of breast cancer patients who have developed lymphedema. The study may lead to a routine clinical implementation of tacrolimus ointment to patients diagnosed with Lymphedema. Regardless of the outcome, the study will benefit the patients and future research in the field of lymphedema.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Odense, Denmark, 5000
        • Department of Plastic Surgery, Odense University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

26 years to 61 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Age between 30-65 years
  • Female
  • Lymphedema diagnosis as a result of breast cancer treatment
  • Active Lymphedema (excessive fluid)
  • Significant lymphedema
  • Grade I-II lymphedema
  • Postmenopausal (Absence/lack of menstruation in at least 12 consecutive months) or continuously usage of contraceptive drugs (Spiral, birth-control pills, implant, transdermal patches, vaginal ring or depot injection). Contraceptive drugs must be used throughout the project and at least three weeks subsequent to the ending of the project (last application of the ointment).
  • Clinically good general condition No lymphedema in the opposite arm (normal arm)
  • Understands the purpose og the study and gives written consent to participate
  • Can read and understand the danish language

Exclusion Criteria:

  • Pregnant, breast-feeding or with wish of pregnancy within the next year
  • Bilateral breast cancer
  • Grade 0, III or IV lymphedema
  • Known allergies for Tacrolimus or and other macrolide
  • Removal of lymph nodes in the opposite armpit
  • Suffers from psychiatric disorders that may affect the participation in the project
  • Reduced kidney or liver function
  • Defect skin-barrier
  • Diagnosed immunodeficiency

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment
Women with stage 1-2 lymphedema due to breast cancer treatment
Drug: Protopic 0.1 % Topical Ointment
Applied in a thin layer covering all of the arm including the armpit and hand once a day for six months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Arm volume from Baseline
Time Frame: Baseline + change in arm volume at 3, 6 and 12 months from baseline
measured with water displacement test. The patient lowers her arm in a basin of water (Bravometer, Novuqare BV, PJ Horst, NL) and arm volume is hereafter read in mL prior to and after the lowering of the arm. This method is established at the department we use for this project. Arm volume of both arms are measured at each consultation.
Baseline + change in arm volume at 3, 6 and 12 months from baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bioimpedance
Time Frame: Baseline + at 3, 6 and 12 month follow-up

Bioimpedance measuring is a tool in estimating the excess liquid in the body. The test is non-invasive and is done by placing electrodes on the skin of the hands and feet similarly to the procedure of an ECG. Signals run through the electrodes connected to a machine that sends electric impulses trough the body and estimates the excess liquid in the extremities.

The test is done at every consultation and has a duration of a couple of minutes. There is no side-effects or discomfort associated to the test.
Baseline + at 3, 6 and 12 month follow-up
Lymphangiography
Time Frame: Baseline + at 6 and 12 month follow-up

An imaging-tool to quantify the lymph-flow and -vessels. ICG is a fluorescent that is absorbed in the lymphatic system and metabolized in the liver with a half-life at 3-4 minutes. The florescent ICG is detectable by cameras at specific wavelengths and is thereby possible to visualize. The outcome of this test is classified into groups: linear pattern and dermal backflow patterns. Dermal backflow patterns can then be subdivided into "splash", "stardust" and "diffuse patterns" via pattern-recognition.

The procedure is done by injecting 0.02 mL ICG subcutaneously in the web space between each finger. Fluorescent imaging of the lymph-vessels and -flow is then obtained by using an infrared camera. There is no exposition of radiation associated with this test.

The ICG lymphangiography is done on both arms. Outcome is measured as the pattern of the lymph-flow.
Baseline + at 6 and 12 month follow-up
Questionnaire: Lymphedema Functioning, Disability and Health questionnaire (Lymph-ICF) LYMPH-ICF
Time Frame: Baseline + at 3, 6 and 12 month follow-up

A Danish validated questionnaire developed specifically for lymphedema-patients. The questionnaire contains 5 domains: lymphedema symptoms, mental function, household activities, mobility activities movement and life and social activities.

29 questions regarding the 5 domains are answered on a scale ranging from 0-10. Raw scores will be transformed into scores ranging from 0 (Worst) to 100 (best) using the original scoring key
Baseline + at 3, 6 and 12 month follow-up
Questionnaire: The disabilities of the arm, shoulder and hand (DASH) questionnaire
Time Frame: Baseline + at 3, 6 and 12 month follow-up

A Danish validated questionnaire developed for patients with disabilities of the arms, shoulders and hands. It includes 38 questions about the patient's ability to perform different actions/movements. The questions are answered on a 5-step scale from not difficult to impossible.

Raw scores will be transformed into scores ranging from 0 (Worst) to 100 (best) using the original scoring key
Baseline + at 3, 6 and 12 month follow-up
Questionnaire: 36-Item Short-Form Health Survey questionnaire (SF-36)
Time Frame: Baseline + at 3, 6 and 12 month follow-up

A Danish validated generic quality of life-questionnaire. The questionnaire includes 36 questions regarding the patient's the general quality of life. The questions are answered on a 3-, 5- and 6-step scale and binary (Yes/No) depending on the question.

Raw scores will be transformed into scores ranging from 0 (Worst) to 100 (best) using the original scoring key
Baseline + at 3, 6 and 12 month follow-up
Arm volume measured with measuring tape
Time Frame: Baseline + at 3, 6 and 12 month follow-up
Manual measuring with measuring tape and then calculated with through volume of a cone formula
Baseline + at 3, 6 and 12 month follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Odense University Hospital

Investigators

  • Study Chair: Jens A Sørensen, MD Prof. PhD, Department of Plastic Surgery at Odense University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 22, 2020

Primary Completion (Actual)

January 6, 2022

Study Completion (Actual)

January 6, 2022

Study Registration Dates

First Submitted

August 28, 2020

First Submitted That Met QC Criteria

September 5, 2020

First Posted (Actual)

September 9, 2020

Study Record Updates

Last Update Posted (Actual)

February 9, 2022

Last Update Submitted That Met QC Criteria

February 8, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Tacrolimus_2020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe